Frontier Neurochem Inc
Description[edit]
| Private | |
| ISIN | 🆔 |
| Industry | Biotech, Pharmaceutical Industry |
| Founded 📆 | 2015 |
| Founder 👔 | |
| Headquarters 🏙️ | , Calgary, Alberta , CANADA |
Area served 🗺️ | |
| Products 📟 | Alkaloids, phytochemicals, neurochemicals, PET imaging and other research reagents |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Frontier Neurochem Laboratories is a Canadian biopharmaceutical company developing nootropic and eugeroic agents of military and civilian interests and new anti-addiction pharmaceuticals. Based in Calgary, Alberta, the company develops, licenses and markets small molecules neurotherapeutics derived from plant-extracted alkaloids compounds and other phytochemicals. Its current strategic focus is the development of new synthetic derivatives of Tabernanthe iboga alkaloids devoid of cardiovascular side-effects[1] [2][3][4].
Primary applications of company products include the field of addiction medicine for the treatment of Substance Use Disorders (SUD), Nootropic cognition therapeutics for Alzheimer's dementia and Nootropic eugeroic therapeutics for wakefulness promotion and sleep recovery. The company compounds portfolio include NC48-spiro[5], a first-in-class non-dopaminergic wakefulness and sleep recovery promoting eugeroic devoid of the addiction and abuse liabilities of dopaminergic-type eugeroics[6]. Frontier NC began as a company focused on providing research-grade alkaloids for the scientific market. As of late 2017, the company was seeking an infusion of US$2,500,000 through Series A and Series B venture capital funds.
Products[edit]
- Ibogamine
- THBC-1278
- THBC-spiro
- Ibogaine hydrochloride
- Ibogaline
- Voacangine
- Tabersonine
- Galantamine hydrobromide
- Rimantadine (Rimanta)
- Memantine
- Mecamylamine
External links[edit]
References[edit]
- ↑ Company website. Retrieved 23 November 2018. http://www.frontier-neurochem.ca/Products.htm
- ↑ Thurner P, et al. (February 2014). "Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine". J. Pharmacol. Exp. Ther. 348 (2): 346–58. doi:10.1124/jpet.113.209643. PMID 24307198.
- ↑ Koenig X, et al. (March 2014). "Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk". Addict. Biol. 19 (2): 237–39. doi:10.1111/j.1369-1600.2012.00447. PMID 22458604.
- ↑ Koenig X, Hilber K (January 2015). "The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation". Molecules. 20 (2): 2208–28. doi:10.3390/molecules20022208. PMC 4382526.
- ↑ Business Week. Retrieved 23 November 2018. http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=51175657.
- ↑ Dunn D, et al. (June 2012). "Wake promoting agents: search for next generation modafinil, lessons learned: part III". Bioorg. Med. Chem. 22 (11): 3751–3. doi:10.1016/j.bmcl.2012.04.031. PMID 22546675.
This article "Frontier Neurochem Laboratories" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Frontier Neurochem Laboratories. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
